IQVIA Beats Q2 Estimates with Strong Revenue Growth and Record R&D Bookings — IQVIA Holdings Inc.

Event summary

IQVIA reported Q2 2026 revenue of $4.37 billion, up 8.7% year-over-year.
R&D Solutions segment generated record net new bookings of over $3.1 billion.
Commercial Solutions saw double-digit growth in patient solutions and commercial engagement services.
Adjusted EBITDA increased by 9.2% year-over-year to $994 million.
Company raised full-year 2026 revenue guidance to between $17.28 billion and $17.48 billion.

The big picture

IQVIA's Q2 2026 results highlight its strategic shift towards a simplified organizational model, enhancing collaboration and efficiency. The company's strong performance in both R&D Solutions and Commercial Solutions segments reflects broader industry trends towards digital transformation and AI-driven healthcare intelligence. With raised full-year guidance, IQVIA is positioning itself for sustained growth into 2027.

What we're watching

Execution Risk: Whether IQVIA can sustain its strong operational performance and meet raised guidance amid a strengthening market environment.
Market Dynamics: How the company's focus on AI solutions and commercial engagement services will impact its competitive positioning in the healthcare intelligence sector.
Financial Strategy: The pace at which IQVIA converts its contracted backlog into revenue, particularly the $9.2 billion expected to convert in the next twelve months.